Asthma and COPD Drugs Market Research Report Information By Disease (COPD and Asthma), By Product (Long-Term Asthma Control Medications and Quick Relief Medications), By Route of Admnistration (Oral and Inhaled), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) – Market Forecast Till 2032.
ID: MRFR/HC/7277-CR | 135 Pages | Author: Rahul Gotadki | February 2020
Speak to Analyst
Request a Free Sample
Global Asthma and COPD Drugs Market Overview
Asthma and COPD Drugs Market Size was valued at USD 25.9 billion in 2022. The Asthma and COPD Drugs Market industry is projected to grow from USD 26.98 Billion in 2023 to USD 38.33 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.3% during the forecast period (2023 - 2032). Rise in prevalence of asthma and COPD and the growth in number of COPD patients are the key market drivers enhancing the market growth.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Asthma and COPD Drugs Market Trends
- Growing prevalence of asthma and COPD to boost market growth
The asthma and chronic obstructive pulmonary disease (COPD) drugs market has experienced significant growth in recent years, and it is expected to continue growing in the coming years. Increasing prevalence of asthma and COPD: The growing prevalence of asthma and COPD worldwide is one of the major factors driving the growth of the asthma and COPD drugs market. According to the World Health Organization (WHO), more than 339 million people worldwide suffer from asthma, and around 251 million people are affected by COPD. Technological advancements: Advancements in drug delivery systems and the development of new treatment options such as biologics and combination therapies have improved patient outcomes and are driving market growth.
Furthermore, combination therapies are becoming increasingly popular for the treatment of asthma and COPD. These therapies combine multiple drugs into a single inhaler, making it easier for patients to manage their conditions. The increasing focus on personalized medicine is also driving market growth. Companies are developing drugs that target specific patient subgroups based on their genetic makeup or other factors, improving treatment outcomes and reducing side effects.
Emerging markets such as India and China are experiencing rapid urbanization and lifestyle changes, leading to an increase in the prevalence of asthma and COPD. This is driving demand for asthma and COPD drugs in these markets. Despite the growth opportunities in the asthma and COPD drugs market, price pressures and patent expirations are putting pressure on companies to innovate and develop cost-effective drugs to remain competitive. Therefore, the asthma and COPD drugs market is expected to continue growing in the coming years.
Asthma and COPD Drugs Market Segment Insights
Asthma and COPD Drugs Market Disease Insights
The Asthma and COPD Drugs Market segmentation, based on disease, includes COPD and asthama. The COPD segment dominated the market in 2022 and is projected to be the faster-growing segment during the forecast period, 2022-2030. COPD is a growing health problem, and its prevalence is expected to continue growing in the coming years. According to the World Health Organization (WHO), COPD is currently the third leading cause of death worldwide, with approximately 3 million deaths annually. Moreover, The prevalence of COPD is particularly high in countries with high rates of smoking, such as China and India. In China, for example, the prevalence of COPD is estimated to be around 13.7%, affecting approximately 100 million people.
July 2020: AstraZeneca recently announced positive results from two phase III trials of its triple-combination therapy for COPD, which combines three drugs in a single inhaler. The trials showed that the therapy improved lung function and reduced exacerbations in patients with moderate to severe COPD.
Asthma and COPD Drugs Market Route of Administration Insights
The Asthma and COPD Drugs Market data has been bifurcated by route of administration into oral and inhaled. The oral segment dominated the market in 2022 and is projected to be the faster-growing segment during the forecast period, 2022-2030. Advancements in drug delivery technologies are also driving growth in the oral segment of the asthma and COPD drugs market. New drug delivery systems such as controlled-release tablets and nanoparticles are improving the efficacy and safety of oral medications. In addition, Emerging markets such as India and China are experiencing rapid urbanization and lifestyle changes, leading to an increase in the prevalence of asthma and COPD. This is driving demand for oral asthma and COPD drugs in these markets.
Figure1: Asthma and COPD Drugs Market, by Route of Administration, 2022 & 2030 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Asthma and COPD Drugs Market Regional Insights
By Region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. North America Asthma and COPD Drugs Market accounted for USD 11.86 billion in 2022 and is expected to exhibit a significant CAGR growth during the study period. The region is driven by the high prevalence of COPD patients in these regions and the availability of advanced healthcare infrastructure. Additionally, government initiatives and funding to support research and development of new antibiotics are expected to drive market growth in these regions. Further, the USA Asthma and COPD Drugs Market held the largest market share, and the Canada Asthma and COPD Drugs Market was the fastest growing market in the North American region due to the high demand for Asthma and COPD Drugs Market and the presence of several major manufacturers in the country.
Further, the major countries studied in the market report are: The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: Asthma and COPD Drugs MARKET SHARE BY REGION 2022 (%)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe Asthma and COPD Drugs Market accounts for the second-largest market share. The Asthma and COPD Drugs market is expected to grow significantly over the forecast period due to the increasing prevalence of asthma patients and the growing demand for effective treatment options.
The Asia-Pacific Asthma and COPD Drugs Market is expected to grow at the fastest CAGR from 2022 to 2030. The market is driven by the increasing prevalence of infectious diseases, rising healthcare expenditure, and the growing demand for effective antibiotic therapies. Moreover, China Asthma and COPD Drugs Market held the largest market share, and the India Asthma and COPD Drugs Market was the fastest growing market in the Asia-Pacific region.
Asthma and COPD Drugs Market Key Market Players & Competitive Insights
Major market players are spending a lot of money on R&D to increase their product lines, which will help the Asthma and COPD Drugs Market grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, with key market developments such as new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the Asthma and COPD Drugs Market industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.
One of the primary business strategies adopted by manufacturers in the Asthma and COPD Drugs Market industry to benefit clients and expand the market sector is to manufacture locally to reduce operating costs. In recent years, Asthma and COPD Drugs Market industry has provided innovative products with some of the most significant benefits. The Asthma and COPD Drugs Market major player such as Pfizer Inc., Teva Pharmaceutical Industries Ltd, Merck & Co Inc., Grifols S A, Novartis AG, Cipla Inc., Abbott, Astellas Pharma, Hoffmann-La Roche Ltd, Glenmark Pharmaceuticals and others are working to expand the market demand by investing in research and development activities.
Pfizer Inc. is a pharmaceutical company that develops and produces a wide range of medicines and vaccines for various diseases and health conditions. The company's portfolio includes products for oncology, immunology, cardiology, and respiratory diseases, including asthma and chronic obstructive pulmonary disease (COPD). In December 2021, Pfizer received approval from the European Medicines Agency (EMA) for its biosimilar referencing Fasenra (benralizumab), a biologic therapy for severe asthma. Furthermore, Pfizer's focus on developing innovative treatments for respiratory diseases such as asthma and COPD demonstrates the company's dedication to improving the lives of patients with these chronic conditions.
Teva Pharmaceutical Industries Ltd is an Israeli multinational pharmaceutical company that specializes in the development, production, and marketing of generic drugs and specialty pharmaceuticals. The company was founded in 1901 and is headquartered in Petah Tikva, Israel. Teva operates in more than 60 countries and has a portfolio of over 3,500 products. Its products cover a wide range of therapeutic areas, including respiratory, central nervous system, cardiovascular, and oncology. Teva is also a major player in the generic drug market. Teva announced in November 2021 that the U.S. Food and Drug Administration (FDA) had approved its ProAir® Digihaler® (albuterol sulfate) Inhalation Powder for the treatment or prevention of bronchospasm in patients aged 4 years and older with reversible obstructive airway disease such as asthma and chronic obstructive pulmonary disease (COPD). ProAir® Digihaler® is a digital inhaler that uses built-in sensors and Bluetooth technology to track inhaler usage and provide feedback to patients and healthcare providers. This approval marks the first-ever digital inhaler with built-in sensors to receive approval from the FDA for the treatment of asthma and COPD.
Key Companies in the Asthma and COPD Drugs Market includes
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd
• Merck & Co Inc.
• Grifols S A
• Novartis AG
• Cipla Inc.
• Abbott
• Astellas Pharma
• Hoffmann-La Roche Ltd
• Glenmark Pharmaceuticals
Asthma and COPD Drugs Market Industry Developments
April 2021:Boehringer Ingelheim and Eli Lilly and Company announced positive results from their Phase IIIb trial of Jardiance (empagliflozin) for the treatment of chronic heart failure with preserved ejection fraction (HFpEF) in patients with and without diabetes, which is a common comorbidity in patients with COPD.
May 2021:AstraZeneca announced that the FDA had approved its self-administered asthma biologic Fasenra Pen (benralizumab) for the treatment of severe eosinophilic asthma.
September 2021:GlaxoSmithKline and Sanofi announced positive results from their Phase III trial of their joint-developed biologic drug Libtayo (cemiplimab) for the treatment of moderate-to-severe asthma.
Asthma and COPD Drugs Market Segmentation
Asthma and COPD Drugs Market Disease Outlook
-
COPD
-
Asthma
Asthma and COPD Drugs Market Product Outlook
-
Long-Term Asthma Control Medications
-
Quick Relief Medications
Asthma and COPD Drugs Market Route of Administration Outlook
Asthma and COPD Drugs Market Distribution Channel Outlook
-
Retail Pharmacies
-
Hospital Pharmacies
-
Online Pharmacies
Asthma and COPD Drugs Market Regional Outlook
-
North America
-
US
-
Canada
-
Europe
-
Germany
-
France
-
UK
-
Italy
-
Spain
-
Rest of Europe
-
Asia-Pacific
-
China
-
Japan
-
India
-
Australia
-
South Korea
-
Australia
-
Rest of Asia-Pacific
-
-
Rest of the World
Report Scope:
| Report Attribute/Metric | Details |
| Market Size 2022 | USD 25.9 billion |
| Market Size 2023 | USD 26.98billion |
| Market Size 2030 | USD 38.33 billion |
| Compound Annual Growth Rate (CAGR) | 5.3% (2023-2032) |
| Base Year | 2022 |
| Market Forecast Period | 2023-2032 |
| Historical Data | 2019 - 2021 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Disease, Product, Route of Administration, Distribution Channel, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and Rest of the World |
| Countries Covered | The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Pfizer Inc., Teva Pharmaceutical Industries Ltd, Merck & Co Inc., Grifols S A, Novartis AG, Cipla Inc., Abbott, Astellas Pharma, Hoffmann-La Roche Ltd, Glenmark Pharmaceuticals and others |
| Key Market Opportunities | Increasing prevalence of COPD patients globally. |
| Key Market Dynamics | The growing demand for effective treatment options. |
Frequently Asked Questions (FAQ) :
The Asthma and COPD Drugs Market size was valued at USD 25.9 Billion in 2022.
The market is projected to grow at a CAGR of 5.3% during the forecast period, 2023-2032.
North America had the largest share in the market
The key players in the market are Pfizer Inc., Teva Pharmaceutical Industries Ltd, Merck & Co Inc., Grifols S A, Novartis AG, Cipla Inc., Abbott, Astellas Pharma, Hoffmann-La Roche Ltd, Glenmark Pharmaceuticals and others.
The COPD disease category dominated the market in 2022.
The oral route of administration had the largest share in the market.
Key Questions Answered
- ✅Global Market Outlook
- ✅In-depth analysis of global and regional trends
- ✅Analyze and identify the major players in the market, their market share, key developments, etc.
- ✅To understand the capability of the major players based on products offered, financials, and strategies.
- ✅Identify disrupting products, companies, and trends.
- ✅To identify opportunities in the market.
- ✅Analyze the key challenges in the market.
- ✅Analyze the regional penetration of players, products, and services in the market.
- ✅Comparison of major players’ financial performance.
- ✅Evaluate strategies adopted by major players.
- ✅Recommendations
Why Choose Market Research Future?
- ✅Vigorous research methodologies for specific market.
- ✅Knowledge partners across the globe
- ✅Large network of partner consultants.
- ✅Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- ✅Trusted by fortune 500 companies/startups/universities/organizations
- ✅Large database of 5000+ markets reports.
- ✅Effective and prompt pre- and post-sales support.
Leading companies partner with us for data-driven Insights.
